M&A Deal Summary

Karo Pharma Acquires Trimb Healthcare AB

On June 24, 2019, Karo Pharma acquired life science company Trimb Healthcare AB from Avista Capital Partners for 3.4B SEK

Acquisition Highlights
  • This is Karo Pharma’s 3rd transaction in the Life Science sector.
  • This is Karo Pharma’s largest (disclosed) transaction.
  • This is Karo Pharma’s 4th transaction in Sweden.

M&A Deal Summary
Date 2019-06-24
Target Trimb Healthcare AB
Sector Life Science
Buyer(s) Karo Pharma
Sellers(s) Avista Capital Partners
Deal Type Add-on Acquisition
Deal Value 3.4B SEK

Target

Trimb Healthcare AB

Stockholm, Sweden
website
Trimb Healthcare AB is a pharmaceutical company focuses on sales, marketing, and development of prescription free (OTC) pharmaceuticals and consumer healthcare products. Trimb owns licenses to, markets and sells a large number of over-the-counter pharmaceuticals and consumer healthcare products. Trimb has a portfolio of leading brands focused on skin care, foot care, oral care, and intimate health categories.

Search 192,611 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Karo Pharma

Stockholm , Sweden

website

Category Company
Founded 1987
Sector Life Science
Employees225
Revenue 3.0B SEK (2021)
DESCRIPTION

Karo Pharma is a specialty pharmaceutical company in the Nordics. The company develops and markets products for pharmacies and directly to the healthcare sector. The product portfolio includes over-the-counter and prescription pharmaceuticals as well as medical devices. Karo Pharma was incorporated in 1987 and is based in Stockholm, Sweden.

DEAL STATS #
Overall 4 of 4
Sector (Life Science) 3 of 3
Type (Add-on Acquisition) 3 of 3
Country (Sweden) 4 of 4
Year (2019) 1 of 1
Size (of disclosed) 1 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2016-11-01 Biophausia AB

Stockholm, Sweden

Biophausia AB is a pharmaceutical company. Biophausia provides cost-effective pharmaceuticals and focuses on three fields: generic products, niche products and original drugs.

Buy kr908M

Seller(S) 1

SELLER

Avista Capital Partners

New York, New York, United States

website

Category Private Equity Firm
Founded 2005
PE ASSETS 6.0B USD
Size Mega
Type Sector Focused
DESCRIPTION

Avista Capital Partners is a private investment firm formed by a group of professionals with roots from DLJ Merchant Banking Partners. Avista makes controlling and minority investments in US based energy, healthcare, and media companies with revenues greater than $25 million. Typical transactions include leverage buyouts, build-ups, and growth capital financings. Avista Capital was formed in 2005 and is based in New York City with an additional office in Houston, Texas.

DEAL STATS #
Overall 27 of 30
Sector (Life Science) 5 of 7
Type (Add-on Acquisition) 13 of 15
Country (Sweden) 1 of 1
Year (2019) 1 of 1
Size (of disclosed) 7 of 11
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2018-12-10 Organogenesis

Canton, Massachusetts, United States

Organogenesis is a provider of regenerative medicine, offering a portfolio of bioactive and acellular biomaterials products for advanced wound care, orthopedics and spine. Organogenesis was established in 1985 and is headquartered in Canton, Massachusetts.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2019-09-03 GCM Holding

Union, California, United States

GCM Holding is a manufacturer of low-to-medium volume, mission-critical precision machined components and assemblies. Based near Chicago’s O’Hare airport, the Company serves large, market customers in the energy, medical equipment, scientific laboratory, and industrial end markets. GCM Holding was founded in 1978 and is based in Union, California.

Buy -
Mergr

Product

Company

Legal